Fibrin/fibrinogen-binding conjugate

US7091325B2 · kind B2 · utility

Assignees

• Baxter Aktiengesellschaft · AT
• Baxter International Inc. · US

Inventors

• Heinz Redl · Wien, AT
• Walter Fuerst · Wien, AT
• Rudolf Kneidinger · Wien, AT
• Sam L. Helgerson · Pasadena, US
• Douglas L. Looker · Lafayette, US
• Elisabeth M. Inman · Pasadena, US
• Jane P. Richards · Longmont, US
• Catalina Wong · Los Angeles, US

Key dates

• Filing date: Dec 30, 2003
• Grant date: Aug 15, 2006
• Expiry date: Dec 30, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF165 C-terminal domain fused to a wound-healing substance such as leptin.